Sees FY23: Membership by year-end in the range of 375,000 to 385,000. Total medical cost ratio in the range of 81.0% to 82.0%. Adjusted EBITDA of approximately $75M-$85M, excluding de novo loss add-backs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CANO:
- Cano Health Plunges as FY23 Outlook Disappoints
- Cano Health Announces Financial Results for the Fourth Quarter and Full Year 2022
- Cano Health options imply 17.7% move in share price post-earnings
- Cano Health Announces Closing of $150 Million Term Loan Facility with Diameter Capital Partners and Rubicon Founders
- Notable open interest changes for February 17th